Rice Hall James & Associates LLC Acquires Shares of 2,332,043 BioCryst Pharmaceuticals, Inc. $BCRX

Rice Hall James & Associates LLC bought a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the second quarter, Holdings Channel.com reports. The fund bought 2,332,043 shares of the biotechnology company’s stock, valued at approximately $23,320,000. BioCryst Pharmaceuticals comprises approximately 1.1% of Rice Hall James & Associates LLC’s investment portfolio, making the stock its 25th biggest holding.

A number of other institutional investors have also modified their holdings of the stock. Larson Financial Group LLC raised its stake in shares of BioCryst Pharmaceuticals by 1,188.0% during the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 3,267 shares in the last quarter. Focus Partners Wealth purchased a new stake in shares of BioCryst Pharmaceuticals in the third quarter valued at approximately $77,000. Mirae Asset Global Investments Co. Ltd. grew its stake in BioCryst Pharmaceuticals by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 2,115 shares in the last quarter. Envestnet Portfolio Solutions Inc. bought a new position in BioCryst Pharmaceuticals in the fourth quarter worth approximately $81,000. Finally, Mercer Global Advisors Inc. ADV purchased a new position in BioCryst Pharmaceuticals during the 3rd quarter worth $81,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Stock Up 2.1%

Shares of BCRX stock opened at $9.94 on Tuesday. The company’s 50 day moving average is $9.53 and its 200 day moving average is $8.86. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of -6.63 and a beta of 0.56. BioCryst Pharmaceuticals, Inc. has a 52-week low of $6.00 and a 52-week high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. The business had revenue of $218.25 million for the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The business’s revenue was up 33.6% compared to the same quarter last year. During the same period last year, the business posted $0.15 EPS. Analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current fiscal year.

Analyst Ratings Changes

BCRX has been the subject of a number of research analyst reports. Royal Bank Of Canada decreased their target price on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. JPMorgan Chase & Co. initiated coverage on BioCryst Pharmaceuticals in a research report on Monday, July 13th. They set a “neutral” rating and a $12.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Wall Street Zen upgraded BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Eight analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $20.60.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.